Kimberly Franks, PA
Physician Assistant · Oklahoma City, OKNPI 1386123644
Payments from drug & device makers
Across 127 payments — averaging $17.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$410
- AstraZeneca$350
- Lilly USA, LLC$236
- Novo Nordisk$220
- Exact Sciences$163
- GSK$109
- plus $774 from 25 others
What the payments were for
- Food & beverage$2,262100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 20 | $410 |
| AstraZeneca | 21 | $350 |
| Lilly USA, LLC | 13 | $236 |
| Novo Nordisk | 14 | $220 |
| Exact Sciences | 10 | $163 |
| GSK | 7 | $109 |
| Boehringer Ingelheim | 6 | $105 |
| Abbott | 5 | $84 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $61 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $48 |
| Astellas Pharma US Inc | 2 | $46 |
| Shield Therapeutics Inc | 1 | $42 |
| Pfizer | 2 | $42 |
| Eisai Inc. | 2 | $29 |
| Dynavax Technologies Corporation | 2 | $29 |
| Johnson & Johnson | 1 | $26 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Gilead | 1 | $24 |
| Novartis | 1 | $20 |
| Hologic Sales And Service, LLC | 1 | $19 |
| Dexcom, Inc. | 1 | $19 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Merck | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $18 |
| Bayer | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Amgen | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Antares Pharma, Inc. | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $12 |
How this compares
$2,262 in reported general payments places this provider in the 80th percentile of 1,491 physician assistant providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 43 | $75,305 |
| TrulicityDulaglutide | 39 | $55,289 |
| EliquisApixaban | 39 | $40,156 |
| FarxigaDapagliflozin Propanediol | 37 | $38,261 |
| JardianceEmpagliflozin | 25 | $35,521 |
| RybelsusSemaglutide | 12 | $25,204 |
| MounjaroTirzepatide | 23 | $20,118 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $19,982 |
| XareltoRivaroxaban | 11 | $17,673 |
| Spiriva RespimatTiotropium Bromide | 20 | $13,593 |
| SymbicortBudesonide/Formoterol Fumarate | 23 | $5,950 |
| Atorvastatin Calcium | 373 | $4,269 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $4,260 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $3,529 |
| Omeprazole | 169 | $3,333 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $220 | $100,50955 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $236 | $75,40762 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $105 | $49,11545 claims |
| AstraZenecaFarxiga, Symbicort | $350 | $44,21260 claims |
| PfizerEliquis | $42 | $40,15639 claims |
| GSKTrelegy Ellipta | $109 | $19,98226 claims |
| Johnson & JohnsonXarelto | $26 | $17,67311 claims |
| AbbVieSynthroid | $410 | $1,77218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,491 physician assistant providers in Oklahoma.
Other physician assistant in Oklahoma City
- Jennifer SmithOklahoma City$134K
- Sarah HawkOklahoma City$23K
- Brooke CromerOklahoma City$14K
- Mary Jane RorickOklahoma City$14K
- Alma HintzeOklahoma City$14K
- Emily McLainOklahoma City$13K
- Deniz AktasOklahoma City$13K
- Jovonne SmithOklahoma City$12K
- Anthony SharpOklahoma City$11K
- Whitney PriceOklahoma City$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.